Adaptimmune Therapeutics plc (ADAP)

NASDAQ: ADAP · IEX Real-Time Price · USD

0.793

+0.103 (14.91%)

At close: Dec 29, 2023, 4:00 PM

0.790

-0.003 (-0.38%)

After-hours: Dec 29, 2023, 7:55 PM EST

Income Statement (Annual)

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	27.15	6.15	3.96	1.12	59.51	37.83	14.2	9.87	0.83
Revenue Growth (YoY)	341.50%	55.36%	252.76%	-98.11%	57.28%	166.47%	43.84%	1096.48%	-
Gross Profit	27.15	6.15	3.96	1.12	59.51	37.83	14.2	9.87	0.83
Selling, General & Admin	63.39	57.31	45.8	43.39	43.6	31.11	23.21	10.38	2.77
Research & Development	127.73	111.09	91.57	97.5	98.27	87.39	63.79	24.14	9.58
Operating Expenses	191.11	168.4	137.36	140.89	141.87	118.49	87	34.51	12.35
Operating Income	-163.97	-162.25	-133.41	-139.77	-82.37	-80.66	-72.8	-24.64	-11.52
Other Expense / Income	-1.01	-4.95	-3.48	-2.85	12.65	-10.97	-2.11	-2.83	0.01
Pretax Income	-162.96	-157.3	-129.93	-136.92	-95.02	-69.69	-70.69	-21.81	-11.53
Income Tax	2.5	0.79	0.16	0.24	0.5	0.45	0.89	0.24	0.08
Net Income	-165.46	-158.09	-130.09	-137.17	-95.51	-70.14	-71.58	-22.06	-11.6
Preferred Dividends	0	0	0	0	0	0	0	14.74	0
Net Income Common	-165.46	-158.09	-130.09	-137.17	-95.51	-70.14	-71.58	-36.79	-11.6
Shares Outstanding (Basic)	967	935	855	630	584	528	425	215	148
Shares Outstanding (Diluted)	967	935	855	630	584	528	425	215	148
Shares Change	3.47%	9.36%	35.72%	7.78%	10.75%	24.23%	97.81%	44.74%	-
EPS (Basic)	-1.02	-1.02	-0.90	-1.32	-0.96	-0.78	-1.02	-1.02	-0.48
EPS (Diluted)	-1.02	-1.02	-0.90	-1.32	-0.96	-0.78	-1.02	-1.02	-0.48
Free Cash Flow	-171.27	2.16	-55.93	-114.1	-108.3	-78.41	-59.67	-34.62	35.47
Free Cash Flow Per Share	-1.06	0.01	-0.39	-1.09	-1.11	-0.89	-0.84	-0.97	1.43
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-603.97%	-2638.58%	-3370.52%	-12457.22%	-138.42%	-213.20%	-512.74%	-249.63%	-1396.48%
Profit Margin	-609.46%	-2570.99%	-3286.81%	-12225.04%	-160.51%	-185.39%	-504.15%	-372.74%	-1406.18%
Free Cash Flow Margin	-630.86%	35.05%	-1413.14%	-10169.25%	-182.00%	-207.25%	-420.30%	-350.76%	4299.27%
EBITDA	-156.88	-150.73	-122.34	-128.91	-87.21	-64.26	-67.4	-21.08	-11.29
EBITDA Margin	-577.88%	-2451.33%	-3090.85%	-11489.57%	-146.55%	-169.86%	-474.72%	-213.54%	-1368.00%
Depreciation & Amortization	6.08	6.57	7.59	8.01	7.81	5.42	3.29	0.74	0.24
EBIT	-162.96	-157.3	-129.93	-136.92	-95.02	-69.69	-70.69	-21.81	-11.53
EBIT Margin	-600.26%	-2558.12%	-3282.72%	-12203.48%	-159.68%	-184.20%	-497.87%	-220.99%	-1397.09%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).